Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
$5.04
+4.6%
$5.56
$2.68
$8.22
$158.78M3.99297,855 shs912,876 shs
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$0.06
-14.5%
$0.07
$0.00
$0.12
$18.29M1.7797,280 shs138,416 shs
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.34
-5.5%
$0.37
$0.80
$1.82
$3.09M2.034,760 shs1,200 shs
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$0.07
$0.09
$0.05
$0.17
N/A0.522,342 shs1,566 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
+4.56%-9.19%-23.98%+22.93%+28.24%
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
-13.24%-9.23%-11.94%-1.67%+84.38%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-5.31%-7.92%-5.36%-13.49%-33.84%
International Stem Cell Co. stock logo
ISCO
International Stem Cell
-14.04%-14.04%-38.80%-24.54%-66.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
0.8521 of 5 stars
3.50.00.00.01.60.80.6
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
3.00
Buy$24.00376.19% Upside
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/A

Current Analyst Ratings

Latest CAPR, ISCO, ICOTF, and ETST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/1/2024
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
$25.18M6.31N/AN/A$0.73 per share6.90
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$50K365.78N/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$7.79MN/AN/AN/A($0.57) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$22.29M-$0.87N/A42.00N/A-88.52%-299.67%-45.54%5/9/2024 (Estimated)
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
-$370KN/A0.00N/A5.77%20.61%11.73%N/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-$1.11M-$0.40N/AN/AN/AN/A-288.85%N/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
-$130K-$0.03N/AN/A-2.68%-2.80%-3.77%N/A

Latest CAPR, ISCO, ICOTF, and ETST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A-$0.04-$0.04-$0.04N/A$1.89 million
2/29/2024Q4 2023
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$0.23-$0.02+$0.21-$0.02$5.80 million$12.09 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/A
1.63
1.63
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
0.10
0.87
0.39
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
0.72
0.72
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A
0.73
0.47

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
21.68%
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/A31.50 million27.72 millionOptionable
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
8309.98 million232.80 millionNot Optionable
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A9.05 millionN/ANot Optionable
International Stem Cell Co. stock logo
ISCO
International Stem Cell
29N/AN/ANot Optionable

CAPR, ISCO, ICOTF, and ETST Headlines

SourceHeadline
Former IFC executive, startup VC launch new $125 million fund for STEM innovations in climate, healthFormer IFC executive, startup VC launch new $125 million fund for STEM innovations in climate, health
msn.com - April 9 at 8:20 AM
Local STEM students complete ‘immersive journey’ in IcelandLocal STEM students complete ‘immersive journey’ in Iceland
springfieldnewssun.com - March 25 at 3:26 AM
Most detailed atlas to date of human blood stem cells could guide future leukemia careMost detailed atlas to date of human blood stem cells could guide future leukemia care
msn.com - March 21 at 5:36 PM
Boyden Norway and ISCO Group Merge to Form Leadership Solutions PowerhouseBoyden Norway and ISCO Group Merge to Form Leadership Solutions Powerhouse
asiaone.com - March 12 at 2:12 PM
Better contact increases stem cell donors availability, shows studyBetter contact increases stem cell donors' availability, shows study
msn.com - March 11 at 3:53 PM
International Womens Day: Hundreds of Upcoming Women Scientists Call for More Inclusivity in STEMInternational Women's Day: Hundreds of Upcoming Women Scientists Call for More Inclusivity in STEM
iaea.org - March 8 at 12:30 PM
New type of stem cell contains potential for knee cartilage regeneration in arthritic miceNew type of stem cell contains potential for knee cartilage regeneration in arthritic mice
msn.com - February 29 at 1:52 PM
Dubai Stem Cell Congress concludes, offering new hope to cancer, diabetes patientsDubai Stem Cell Congress concludes, offering new hope to cancer, diabetes patients
msn.com - February 28 at 8:16 AM
Dubai Stem Cell Congress begins featuring 30 International SpeakersDubai Stem Cell Congress begins featuring 30 International Speakers
msn.com - February 26 at 1:46 PM
Stem cell donors needed to save young child’s life and that of many othersStem cell donors needed to save young child’s life and that of many others
msn.com - February 15 at 10:43 AM
International Stem Cell Corp ISCOInternational Stem Cell Corp ISCO
morningstar.com - January 13 at 3:42 PM
House Majority Leader Steve Scalise to undergo stem cell transplantHouse Majority Leader Steve Scalise to undergo stem cell transplant
msn.com - January 5 at 3:50 PM
Pioneering Stem Cell Therapy for Progressive Multiple Sclerosis Shows PromisePioneering Stem Cell Therapy for Progressive Multiple Sclerosis Shows Promise
neurosciencenews.com - November 27 at 10:35 AM
Jim Corbett witnessed Cell Based Medicine in the MakingJim Corbett witnessed Cell Based Medicine in the Making
msn.com - November 10 at 8:29 AM
ISSCR and Cell Press renew publishing agreement for Stem Cell ReportsISSCR and Cell Press renew publishing agreement for Stem Cell Reports
eurekalert.org - November 6 at 11:23 PM
Checklist introduced to promote global best practices for human stem cell research'Checklist' introduced to promote global best practices for human stem cell research
medicalxpress.com - September 14 at 2:47 PM
How stem cells age and why this makes us grow oldHow stem cells age and why this makes us grow old
nature.com - July 25 at 10:16 AM
No place like home: anatomy and function of the stem cell nicheNo place like home: anatomy and function of the stem cell niche
nature.com - July 10 at 11:56 PM
In collaboration with ISCO, EFMS, Servier launches new treatment for pancreatic cancer in EgyptIn collaboration with ISCO, EFMS, Servier launches new treatment for pancreatic cancer in Egypt
zawya.com - July 7 at 8:46 AM
Bayer claims early lead in Parkinsons stem cell therapyBayer claims early lead in Parkinson's stem cell therapy
reuters.com - June 28 at 7:21 AM
Scientists have created synthetic embryos from stem cells – it could help us better understand infertility and miscarriageScientists have created synthetic embryos from stem cells – it could help us better understand infertility and miscarriage
theconversation.com - June 16 at 6:25 PM
Scientists create synthetic human embryos from stem cells: reportScientists create 'synthetic human embryos' from stem cells: report
msn.com - June 14 at 6:29 PM
Maximizing the function and potential of stem cell-based treatments for patients with Type 1 diabetesMaximizing the function and potential of stem cell-based treatments for patients with Type 1 diabetes
news-medical.net - June 13 at 3:25 PM
The ISSCR releases global standards to enhance rigor and reproducibility of stem cell researchThe ISSCR releases global standards to enhance rigor and reproducibility of stem cell research
eurekalert.org - June 5 at 11:11 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Capricor Therapeutics logo

Capricor Therapeutics

NASDAQ:CAPR
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Earth Science Tech logo

Earth Science Tech

OTCMKTS:ETST
Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.
iCo Therapeutics logo

iCo Therapeutics

OTCMKTS:ICOTF
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.
International Stem Cell logo

International Stem Cell

OTCMKTS:ISCO
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.